New cancer drug targets notorious KRAS mutation in first human tests
Disease control
Recruiting now
This is the first human study of an experimental drug called QTX3034 for people with advanced solid tumors that have a specific genetic change called KRASG12D. The trial aims to find the safest dose and see how well the drug works, either alone or combined with an existing cancer…
Phase: PHASE1 • Sponsor: Quanta Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC